An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors

Onali, Sara;Pugliese, Daniela;Caprioli, Flavio Andrea;Orlando, Ambrogio;Biancone, Livia;Nardone, Olga Maria;Imperatore, Nicola;Fiorino, Gionata;Cappello, Maria;Viola, Anna;Principi, Maria Beatrice;Bezzio, Cristina;Aratari, Annalisa;Carparelli, Sonia;Mazzuoli, Silvia;Manguso, Francesco;Grossi, Laurino;Bodini, Giorgia;Ribaldone, Davide;Mocci, Giammarco;Miranda, Agnese;Minerba, Luigi;Favale, Agnese;Grova, Mauro;Scucchi, Ludovica;Segato, Simone;Fries, Walter;Castiglione, Fabiana;Armuzzi, Alessandro;Fantini, Massimo C

2022-01-01

---

Abstract

The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) in which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. The aim of this study was to compare, in a large multicenter observational retrospective cohort, the effectiveness of ustekinumab and vedolizumab as second-line therapies, as assessed by clinical and objective outcomes including endoscopy and gastrointestinal imaging.